by Sean Hutchinson | Aug 9, 2022 | US & International
Background Under the Civil Code of China, “likenesses” of individuals are protected as personality rights. Specifically, no party is entitled to use an image of a person without that person’s consent. This is known as the “right to likeness” and is detailed in Article...
by Alex Bajjon | Jul 7, 2022 | US & International
Excess Claims Fees Up until now, there have been no excess claims fees in Canada and therefore minimal or no incentives for applicants to limit the number of claims in their patent applications. Under the new regime, excess claims fees will be payable for claim sets...
by Eddie Bishop | Apr 25, 2022 | US & International
Questions on the European SPC Regulation, in particular in relation to SPCs for combination products, have been raised at the CJEU many times over the years. It is therefore hoped that this newest referral may provide some much-needed clarity. Background For an SPC to...
by Dr David Eyre | Jan 21, 2022 | Briefings, EPO, UPC, US & International
Background to the UPC The European Unitary Patent is intended to provide a further and more efficient option for enforcement of patent rights across the European Union. It is based on the European patent system which is overseen by the European Patent Organisation...
by Sean Hutchinson | Oct 1, 2021 | Briefings, US & International
Background In 2008, the State Council of China issued its “Outline of the National Intellectual Property Strategy”, which set a target of increasing the administration and use of IP rights in China by 2020. Last year, the State Council Information Office...
by Eddie Bishop | Oct 1, 2021 | Briefings, US & International
Belcher’s patent related to a high-pH formulation of L-epinephrine (L-adrenaline) and was granted with a claim to a formulation of pH 2.8-3.3. The formulation of L-epinephrine was also the subject of a new drug application before the FDA. Hospira, who were...
Recent Comments